Dr. Douglas W. Losordo is the chief medical officer and senior vice president of Clinical, Medical and Regulatory Affairs of Caladrius Biosciences, Inc., clinical professor of medicine at the New York University Langone Medical Center and adjunct professor of medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.
Dr. Losordo’s career has been dedicated to patient care and to the development of novel therapeutics aimed at the reversal or repair of chronic conditions such as heart failure, critical limb ischemia, cancer, diabetes and autoimmune disease.
A native of Brooklyn, New York, he received his medical degree from the University of Vermont. Dr. Losordo completed an internship, residency and fellowship at St. Elizabeth’s Medical, Boston, Massachusetts, where he subsequently joined the faculty, working with the late Jeff Isner, M.D., to develop a program in gene therapy and cell-based tissue repair. Dr. Losordo’s group has executed the full translational medicine paradigm: identifying potential therapeutic approaches in the laboratory, investigating these strategies in pre–clinical/IND–enabling models and designing and executing first–in–human and proof–of–concept clinical trials as the study sponsor/IND–holder. His work has included developing VEGF gene therapy for myocardial ischemia and diabetic neuropathy, CD34+ cell therapy for refractory angina, critical limb ischemia, severe claudication and coronary microvascular dysfunction and regulatory T cell therapy for autoimmune disease. Two of these candidates advanced to phase 3. At Caladrius, Dr. Losordo has recently initiated a study of CD34 cell therapy for critical limb ischemia targeting conditional approval under the new Japanese regulatory rules governing regenerative therapies. In addition to his own work, Dr. Losordo has also mentored numerous scientists and physician-scientists from around the world who now have their own independent programs in translational research.